A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors
暂无分享,去创建一个
E. Schuuring | F. van Coevorden | H. Gelderblom | J. Gietema | R. Mathijssen | A. Reyners | N. Steeghs | A. ter Elst | A. Suurmeijer | I. Desar | P. Boonstra | M. Tibbesma | F. Atrafi | W. V. D. van der Graaf | J. Overbosch | J. Maier | S. Farag | L. J. Bosman | Sheima Farag
[1] V. Papadimitrakopoulou,et al. Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer , 2016, Clinical Cancer Research.
[2] C. Paweletz,et al. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] H. Do,et al. Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. , 2016, Lung cancer.
[4] Suzanne E Dahlberg,et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. , 2016, JAMA oncology.
[5] Ryan D. Morin,et al. Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies , 2016, Molecular Cancer Research.
[6] Kyoung-Mee Kim,et al. Detecting Primary KIT Mutations in Presurgical Plasma of Patients with Gastrointestinal Stromal Tumor , 2016, Molecular Diagnosis & Therapy.
[7] H. Groen,et al. Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing , 2016, PloS one.
[8] H. Guadalajara,et al. KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients , 2016, International journal of molecular sciences.
[9] Meizhuo Zhang,et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance , 2016, Scientific Reports.
[10] M. Ychou,et al. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care , 2016, Clinical Cancer Research.
[11] S. Hirota,et al. Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor , 2016, Oncology.
[12] J. Blay,et al. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial , 2016, BMC Cancer.
[13] Elena Pereira,et al. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers , 2015, PloS one.
[14] A. Marchetti,et al. Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] I. Hudecova,et al. Digital PCR analysis of circulating nucleic acids. , 2015, Clinical biochemistry.
[16] H. Yao,et al. Clinicopathological significance of c-KIT mutation in gastrointestinal stromal tumors: a systematic review and meta-analysis , 2015, Scientific Reports.
[17] Jorge S. Reis-Filho,et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer , 2015, Science Translational Medicine.
[18] Alexander Dobrovic,et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations , 2015, Scientific Reports.
[19] Beatriz Bellosillo,et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.
[20] E. Felip,et al. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. , 2015, JAMA oncology.
[21] T. Mok,et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy , 2015, Clinical Cancer Research.
[22] Kyoung-Mee Kim,et al. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor , 2015, Targeted Oncology.
[23] J. Jónasson,et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[25] Charles Swanton,et al. Tumour heterogeneity and the evolution of polyclonal drug resistance , 2014, Molecular oncology.
[26] C. Yoo,et al. Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] L. Diaz,et al. Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[29] C. Paweletz,et al. Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA , 2014, Clinical Cancer Research.
[30] M. Schlaak,et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations , 2014, BMC Cancer.
[31] T. Williams,et al. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. , 2013, Clinical biochemistry.
[32] F. Nicolantonio,et al. Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.
[33] H. Groen,et al. Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome , 2013, PloS one.
[34] D. Niederwieser,et al. Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA , 2013, Clinical Cancer Research.
[35] J. Blay,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[36] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[37] Jeff Mellen,et al. High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number , 2011, Analytical chemistry.
[38] Klaus Pantel,et al. Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.
[39] M. Pantaleo,et al. The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting , 2011, Journal of Translational Medicine.
[40] F. Duffaud. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] J. Lasota,et al. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. , 2009, Archives of pathology & laboratory medicine.
[42] K. Pantel,et al. Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer , 2009, Clinical Cancer Research.
[43] D. Armbruster,et al. Limit of blank, limit of detection and limit of quantitation. , 2008, The Clinical biochemist. Reviews.
[44] M. Heinrich,et al. Molecular pathobiology of gastrointestinal stromal sarcomas. , 2008, Annual review of pathology.
[45] Michael Worobey,et al. The Isolation of Nucleic Acids from Fixed, Paraffin-Embedded Tissues–Which Methods Are Useful When? , 2007, PloS one.
[46] K. Owzar,et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts) , 2007 .
[47] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[48] Frank Diehl,et al. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions , 2006, Nature Methods.
[49] E. Wardelmann,et al. Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate , 2006, Clinical Cancer Research.
[50] C. Antonescu,et al. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.
[51] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[52] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[53] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[54] S. Goodman,et al. Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.